



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: James P. HOEFFLER *et al.*  
Title: SINGLE CHAIN MONOCLONAL ANTIBODY FUSION REAGENTS THAT REGULATE TRANSCRIPTION *IN VIVO*  
Application No.: 09/939,769  
Filing Date: August 28, 2001  
Examiner: Stephen L. Rawlings  
Art Unit: 1642

#  
1512  
KO  
6-803

**AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR SEQUENCE LISTING UNDER 37 C.F.R. § 1.821-1.825**

Mail Stop NON-FEE AMENDMENT  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This is a reply to the Office communication mailed April 29, 2003, in the above-referenced application. Prior to reconsideration, Applicants request that the Office enter the following amendments.

**In the Specification**

Please amend the specification as follows. In accordance with 37 CFR § 1.121, a marked up version showing the changes in the specification is attached.

Page 7, delete paragraph starting at line 3 ending at line 5 and replace this paragraph with the following.

FIG. 2 Shows schematic representations of example intracellular targeting sequences (DPKKKRKV, SEQ ID NO: 92; SEKDEL, SEQ ID NO: 93; MSVLTPLLLRGLTGSARRLPVRAKIHSL, SEQ ID NO:1; and METDLLLWVLLLWVPGSTGD, SEQ ID NO:2, respectively) for use with single chain

51